Q-omics provides the consensus-scored MRPS25 profile across patient tissues and cancer cell-line models. MRPS25 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPS25 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, MRPS25 protein abundance shows 25,991 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where MRPS25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS25 survival associations across molecular data types. MRPS25 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS25 RNA expression–survival associations across cancer types. High MRPS25 expression shows unfavorable associations in KIRC, SKCM, KICH and UCEC, but favorable associations in READ and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPS25 RNA expression.
This table summarizes MRPS25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS25 shows lower tumor expression in KIRC and higher tumor expression in LIHC, THCA, STAD, UCEC and COAD. The KIRC box plot shows higher MRPS25 RNA expression in normal versus tumor tissue (log2 FC = −0.935, t-test p < 0.001).
This table shows molecular features associated with MRPS25 in patient tissues and cancer cell lines. In patient samples, MRPS25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
